FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. There are presented an antibody and its antigen-binding fragment specifically binding human colony-stimulating factor-1 receptor (CSF-1R) characterised by sequences of complementary-determining regions (CDR). There are also disclosed a nucleic acid coding the antibody according to the invention or its antigen-binding fragment, a vector providing the expression of the antibody and its antigen-binding fragment, and a pharmaceutical composition applicable in treating the diseases associated with an inflammation or an autoimmunity, or cancer.
EFFECT: invention can find further application in diagnosing and therapy of the CSF-1 associated diseases.
23 cl, 18 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
Authors
Dates
2015-04-10—Published
2009-03-11—Filed